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ﻢﯿﺣﺮﻟا ﻦﻤﺣﺮﻟا ﮫﻠﻟا ﻢﺳ 
ﻰﻟﺎﻌﺗ لﺎﻗ: 
} ِﮫﻠﻟا ِﺮﻛِﺬِﻟ ﻢُُﮭﺑﻮُﻠﻗ َﻊَﺸَﺨﺗ َنأ اﻮﻨََﻣآ َﻦﯾﺬﱠﻠِﻟ ِنَﺄﯾ َﻢَﻟأ لﺎﻄﻓ ﻞﺒﻗ ﻦﻣ بﺎﺘﻜﻟا اﻮﺗوأ ﻦﯾﺬﻟﺎﻛ اﻮﻧﻮﻜﯾ ﻻو ﻖﺤﻟا ﻦﻣ لﺰﻧﺎﻣو  ﻢﮭﯿﻠﻋ ﺪﻣﻷا
{نﻮﻘﺳﺎﻓ ﻢﮭﻨﻣ ﺮﯿﺜﻛ و ﻢﮭﺑﻮﻠﻗ ﺖﺴﻘﻓ 
 ﺔﯾﻵا دﯾدﺣﻟا ةروﺳ) 16 (.  
Allah (S.W.T) said:  
{Has not the time come for the hearts of those who believe (in the Oneness of Allah, Islamic 
Monotheism) to be affected by Allah’s Reminder (this Qur’an), and that which has been 
revealed of the truth, lest they become as those who received the Scripture before (i.e. Jews 
and Christians), and the term was prolonged for them and so their hearts were hardened? And 
many of them were Faasiquun (the rebellious, the disobedient to Allah}.  
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Abstract (in English): 
Background: Asthma is a chronic disease and one of the commonest long term respiratory 
diseases that affects millions of adults around the globe; in both developed and developing 
countries. The disease remains one of the global public health problem that affects people of 
all ages with a prevalence of 334 million people. The prevalence and economic burden of 
asthma is increasing in Sudan and other African countries where the disease is not given much 
attention.  
General objective: To perform a cost-effectiveness study on corticosteroid preparations in 
asthmatic patients at Alshaab teaching hospital Khartoum, Khartoum state, Sudan, 2015-2016.  
Methods: This study was designed to be a hospital-based, cross sectional, retrospective and 
prospective study, which enrolled 100 adult asthmatic patients. The data were collected using 
EQ-5D-3L Arabic version questionnaire and data collection forms and analyzed using SPSS 
(version IBM). The medications that were evaluated are: Hydrocortisone injection 100mg, 
prednisolone tablet 5mg and Symbicort (budesonide/formeterol) inhaler 160/4.5 ug/dose. 
Results: In this study, out of 100 patients that were enrolled, the majority of them (58%) were 
females, fell within 16-40 age group category (38%) and were married (82%). Symbicort 
inhaler was found to be the most expensive preparation with a direct medical cost of 1949.97 
SDG ($291) per patient per 8 months. However, prednisolone tablet was found to be least 
expensive with a direct medical cost of 444.35 SDG ($ 66.3) per patient per 8 months, the most 
reasonable alternative with regard to effectiveness as well as the most efficient (cost-effective) 
preparation with regard to effectiveness-adjusted costs (with ACER= 683.6 SDG/HRQoL). 
Conclusion: This study concluded that the prevalence of asthma and utilization of 
pharmaceutical products and services among adult asthmatic patients in ASH were more in 
female patients (58%) and those in 16-40 age group category (38%). Symbicort inhaler was 
concluded to be the most expensive preparation and Prednisolone tablet was concluded to be 
 x 
 
the least expensive and most cost-effective preparation among the three preparations that were 
studied in ASH. 































ﯾﺼﯿﺐ ﻣﻼﯾﯿﻦ اﻟﺒﺸﺮ اﻟﺒﺎﻟﻐﯿﻦ  و اﻛﺜﺮ اﻣﺮاض اﻟﺠﮭﺎز اﻟﺘﻨﻔﺴﻲ اﻧﺘﺸﺎراً  ﻣﻦ واﺣﺪ وﯾﻌﺘﺒﺮ اﻟﺮﺑﻮ اﺣﺪ اﻻﻣﺮاض اﻟﻤﺰﻣﻨﺔ اﻟﺨﻠﻔﯿﺔ:
ﻓﻲ ﻛﻞ  اﻟﺒﻠﺪان اﻟﻨﺎﻣﯿﺔ واﻟﻤﺘﻘﺪﻣﺔ.ﯾﻈﻞ اﻟﺮﺑﻮ اﺣﺪ اﻟﻤﺸﺎﻛﻞ اﻟﻌﺎﻟﻤﯿﺔ ﻟﻠﺼﺤﺔ اﻟﻌﺎﻣﺔ.أﺣﺪث  .ﻣﺨﺘﻠﻒ اﻷﻋﻤﺎر وﻣﻦ  ﺣﻮل اﻟﻌﺎﻟﻢ 
ﻣﻠﯿﻮن ﺷﺨﺺ ﺑﻤﺨﺘﻠﻒ اﻻﻋﻤﺎر واﻻﻋﺮاق ﯾﻌﺎﻧﻮن ﻣﻦ اﻟﺮﺑﻮ.اﻟﻌﺐء اﻟﻤﺮﺿﻲ  433اﻟﺪراﺳﺎت ﻋﻦ اﻧﺘﺸﺎر اﻟﺮﺑﻮ وﺟﺪت ان 
ﻟﻨﺎﺗﺠﺔ ﺿﺔ واﻟﻮﻓﯿﺎت ااﻟﻠﺮﺑﻮ ﻋﻠﻲ اﻟﺤﻜﻮﻣﺎت واﻷﻧﻈﻤﺔ اﻟﺼﺤﯿﺔ واﻟﻤﺮﺿﻲ واﻟﻌﻮاﺋﻞ ﻓﻲ ﺗﺰاﯾﺪ ﻋﻠﻲ ﻣﺴﺘﻮي اﻟﻌﺎﻟﻢ و ﻛﺬﻟﻚ اﻟﻤﺮ
دي ﻟﻌﺐء اﻟﻤﺮﺿﻲ واﻻﻗﺘﺼﺎاوﻓﻰ اﻟﺴﻮدان ﻓﺎن   ﻣﻦ اﻟﺮﺑﻮ اﻟﺘﻲ اﺻﺒﺤﺖ ﻣﺸﻜﻠﺔ ﻓﻲ ﻛﺜﯿﺮ ﻣﻦ اﻟﺪول ﺧﺼﻮﺻﺎ اﻟﺪول اﻟﻨﺎﻣﯿﺔ.
 اﻟﺒﻠﺪان اﻻﻓﺮﯾﻘﯿﺔ اﻻﺧﺮي اﻟﺘﻲ ﻻ ﯾﻠﻘﻲ اﻟﺮﺑﻮ ﻓﯿﮭﺎ اھﺘﻤﺎﻣﺎ ﻛﺎﻓﯿﺎ.ﻓﻰ  وﻛﺬﻟﻚ ﻟﻠﺮﺑﻮ ﻓﻲ ﺣﺎﻟﺔ ﻣﺘﺰاﯾﺪة 
دراﺳﺔ اﻟﻔﻌﺎﻟﯿﺔ ﻣﻦ ﺣﯿﺚ اﻟﺘﻜﻠﻔﺔ ﻟﺘﺮاﻛﯿﺐ ﻣﺨﺘﻠﻔﺔ ﻷدوﯾﺔ اﻻﺳﺘﺮوﯾﺪات  ﻓﻲ ﻣﺮﺿﻲ اﻟﺮﺑﻮ اﻟﺒﺎﻟﻐﯿﻦ ﻓﻲ ﻣﺴﺘﻔﺸﻲ اﻷھﺪاف اﻟﻌﺎﻣﺔ: 
 6102-5102اﻟﺴﻮدان,اﻟﺸﻌﺐ اﻟﺘﻌﻠﯿﻤﻲ,اﻟﺨﺮطﻮم,
ﻣﺌﺔ اﻟﻌﯿﻨﺔ وﺗﺘﻀﻤﻦ  ﺟﺪﯾﺪة ﻗﺪﯾﻤﺔ و ﺣﺎﻻت ﺗﺸﻤﻞ : ﺗﻢ ﺗﺼﻤﯿﻢ ھﺬه اﻟﺪراﺳﺔ ﻟﺘﻜﻮن دراﺳﺔ ﻣﻘﻄﻌﯿﺔ ﻣﺤﻮرھﺎ اﻟﻤﺴﺘﺸﻔﻲ  اﻟﻄﺮﯾﻘﺔ
ﺗﻢ  .6102ﺒﺮ ﻟﻲ دﯾﺴﻤإﻣﻦ ﻣﺮﺿﻲ اﻟﺮﺑﻮ اﻟﺒﺎﻟﻐﯿﻦ اﻟﺬﯾﻦ ﺗﻢ وﺻﻒ اﻻﺳﺘﯿﺮوﯾﺪات ﻟﮭﻢ ﻓﻲ ﻣﺴﺘﺸﻔﻲ اﻟﺸﻌﺐ ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ ﻣﺎﯾﻮ 
ﺗﺤﻠﯿﻞ اﻟﺒﯿﺎﻧﺎت وﺻﻔﯿﺎ وﺗﺤﻠﯿﻼ ﻛﻤﺎ ﺗﻢ (  )L3-D5-QEﺟﻤﻊ اﻟﺒﺎﯾﺎﻧﺎت ﺑﺎﺳﺘﺨﺪام ﻧﻤﺎذج ﺟﻤﻊ اﻟﺒﯿﺎﻧﺎت واﺳﺘﺒﯿﺎن ﻣﻦ ﻧﻮع 
  .)MBI noisreV( SSPSﺑﺎﺳﺘﺨﺪام 
اﻋﻤﺎرھﻢ  ﺖ( ﻛﺎﻧ%83( ﻛﺎﻧﻮ ﻣﻦ اﻹﻧﺎث واﻏﻠﺒﯿﺘﮭﻢ)%85ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ﻣﻦ اﻟﻤﺌﺔ ﻣﺮﯾﺾ اﻟﺘﺎﺑﻌﯿﻦ ﻟﻠﺪراﺳﺔ اﻻﻏﻠﺒﯿﺔ ) اﻟﻨﺘﺎﺋﺞ:
 ن ﺑﺨﺎخ ﺳﯿﻤﺒﻜﻮرت ھﻮ اﻛﺜﺮ اﻟﺘﺮاﻛﯿﺐ ﻧﻜﻠﻔﺔأاﻟﺪراﺳﺔ وﺟﺪ  وﻣﻦ (.%28ﻣﺘﺰوﺟﻮن )ا واﻻﻏﻠﺒﯿﺔ ﻛﺎﻧﻮ ﺳﻨﺔ 04-61ﺔ ﺑﯿﻦ واﻗﻌ
ﺣﺒﻮب  ووﺿﺢ إن .ﻟﻜﻞ ﻣﺮﯾﺾ ﻓﻲ ﻛﻞ ﺛﻤﺎﻧﯿﺔ أﺷﮭﺮاً دوﻻر 192ﻣﺎ ﯾﻌﺎدل إى  .سج 79.9491ﺑﺘﻜﻠﻔﺔ ﻣﺒﺎﺷﺮة ﻗﺪرھﺎ  و
دوﻻرﻟﻜﻞ ﻣﺮﯾﺾ ﻓﻲ ﻛﻞ  3.66ﻣﺎ ﯾﻌﺎدل إي  .سج 53.444  اﻗﻞ اﻟﺘﺮاﻛﯿﺐ ﻧﻜﻠﻔﺔ ﺑﺘﻜﻠﻔﺔ ﻣﺒﺎﺷﺮة ﻗﺪرھﺎ ﻰھ ﺒﺮﯾﺪﻧﺰوﻟﻮناﻟ
 6.386 = RECA( ) وﺟﺪ اﻧﮭﺎ اﻻﻛﺜﺮ ﻓﻌﺎﻟﯿﺔ واﻻﻛﺜﺮ ﻓﻌﺎﻟﯿﺔ ﻣﻦ ﺣﯿﺚ اﻟﺘﻜﻠﻔﺔ ﻣﻘﺎرﻧﺔ ﻣﻊ ﺑﺎﻗﻲ اﻟﺘﺮﻛﯿﺒﺎت ,ﺛﻤﺎﻧﯿﺔ أﺷﮭﺮ
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ھﺬه اﻟﺪراﺳﺔ وﺟﺪت ان اﻧﺘﺸﺎر اﻟﺮﺑﻮ واﺳﺘﺨﺪام اﻟﻤﻨﺘﺠﺎت اﻟﺼﺤﯿﺔ واﻟﺨﺪﻣﺎت اﻟﻌﻼﺟﯿﺔ ﺑﯿﻦ اﻟﻤﺮﺿﻲ اﻟﺒﺎﻟﻐﯿﻦ ﻓﻲ اﻟﺨﻼﺻﺔ: 
(. ﺑﺨﺎخ ﺳﯿﻤﺒﻜﻮرت %83) 04-61( واﻟﻤﺮﺿﻲ اﻟﺬﯾﻦ ﺗﻘﻊ اﻋﻤﺎرھﻢ ﺑﻲ %85ﻣﺴﺘﺸﻔﻲ اﻟﺸﻌﺐ ﻛﺎن اﻛﺜﺮ ﻣﻦ ﻗﺒﻞ اﻹﻧﺎث )
ﯿﺚ ذات اﻟﺘﻜﻠﻔﺔ اﻻﻗﻞ و اﻻﻛﺜﺮ ﻓﻌﺎﻟﯿﺔ واﻻﻛﺜﺮ ﻓﻌﺎﻟﯿﺔ ﻣﻦ ﺣوﺟﺪ اﻧﮫ اﻻﻋﻠﻲ ﺗﻜﻠﻔﺔ  ﺑﯿﻦ اﻟﺘﺮﻛﯿﺒﺎت و ﺣﺒﻮب ﺑﺮﯾﺪﻧﺰوﻟﻮن ﻛﺎﻧﺖ 
 .اﻟﺘﻜﻠﻔﺔ ﺑﯿﻦ اﻟﺘﺮاﻛﯿﺐ اﻟﺜﻼﺛﺔ اﻟﺘﻲ ﺗﻤﺖ دراﺳﺘﮭﺎ ﻓﻲ ﻣﺴﺘﺸﻔﻲ اﻟﺸﻌﺐ اﻟﺘﻌﻠﯿﻤﻲ
